News, Events and Social Media

May 2024 has been an exceptionally productive month for the University of Glasgow Heart Failure Research Group, with 26 publications (listed below) and counting! Notably, these include 14 simultaneous publications at the recent European Society of Cardiology (ESC) Heart Failure Association (HFA) congress in Lisbon (11-14th May 2024), and one simultaneous publication at the EuroPCR 2024 congress in Paris (14-17th May 2024). Among these publications, one is featured in the New England Journal of Medicine and another in Nature Medicine.

SEQUOIA-HCM (three late-breaking clinical trial presentations at ESC-HFA including one by Dr Caroline Coats from the University of Glasgow)

1. Maron MS, Masri A, Nassif ME, Barriales-Villa R, Arad M, Cardim N, Choudhury L, Claggett B, Coats CJ, Düngen HD, Garcia-Pavia P, Hagège AA, Januzzi JL, Lee MMY, Lewis GD, Ma CS, Michels M, Olivotto I, Oreziak A, Owens AT, Spertus JA, Solomon SD, Tfelt-Hansen J, van Sinttruije M, Veselka J, Watkins H, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Abraham TP; SEQUOIA-HCM Investigators. Aficamten for Symptomatic Obstructive Hypertrophic N Engl J Med. 2024 May 13. doi: 10.1056/NEJMoa2401424. Epub ahead of print. PMID: 38739079.

STEP-HFpEF Program (two late-breaking clinical trial presentations at ESC-HFA including one by Professor Mark Petrie from the University of Glasgow)

1. Petrie MC, Borlaug BA, Butler J, Davies MJ, Kitzman DW, Shah SJ, Verma S, Jensen TJ, Einfeldt MN, Liisberg K, Perna E, Sharma K, Ezekowitz JA, Fu M, Melenovský V, Ito H, Lelonek M, Kosiborod MN. Semaglutide and NTproBNP in Obesity-Related HFpEF: Insights from STEP-HFpEF Program. J Am Coll Cardiol. Online 2024 May 13. https://doi.org/10.1016/j.jacc.2024.04.022
2. Shah SJ, Sharma K, Borlaug BA, Butler J, Davies M, Kitzman DW, Petrie MC, Verma S, Patel S, Chinnakondepalli KM, Einfeldt MN, Jensen TJ, Rasmussen S, Asleh R, Ben-Gal T, Kosiborod MN. Semaglutide and Diuretic Use in Obesity-Related Heart Failure with Preserved Ejection Fraction: A Pooled Analysis of the STEP-HFpEF and STEP-HFpEF-DM trials. Eur Heart J. 2024 May 13:ehae322. doi: 10.1093/eurheartj/ehae322. Epub ahead of print. PMID: 38739118.

CONGEST-HF (late-breaking clinical trial presentation at ESC-HFA by Dr James Curtain from the University of Glasgow)

1. Curtain JP, Talebi A, McIntosh A, McConnachie A, O'Donnell J, Welsh P, Osmanska J, Lee MMY, Sonecki P, Akl T, Seo J, Gopinathan V, Hurwitz J, Thiagarajan S, Pettit S, Kalra PR, Patel RK, Mark PB, Lang NN, McMurray JJV, Petrie MC, Gardner RS, Jhund Measuring congestion with a non-invasive monitoring device in heart failure and haemodialysis: CONGEST-HF. Eur J Heart Fail. 2024 May 13. doi: 10.1002/ejhf.3290. Epub ahead of print. PMID: 38741283.

REALIZE-K (late-breaking clinical trial at ESC-HFA)

1. Kosiborod M, Cherney D, Connelly K, Desai AS, Guimarães PO, Kuthi L, Trindade AL, Madrini V, Merkely B, Villota JN, Squire I, Testani JM, Vaclavik J, Verma S, Wranicz J, Dahl M, Eudicone JM, Lovisa Friberg L, Petrie Sodium zirconium cyclosilicate in patients with HFrEF and hyperkalemia: REALIZE-K rationale, design, and baseline characteristics. JACC Heart Fail. Online 2024 May 13. https://doi.org/10.1016/j.jchf.2024.05.003
2. Neuen BL, Claggett BL, Perkovic V, Jardine M, Heerspink HJL, Mahaffey KW, McMurray JJV, Solomon SD, Vaduganathan M. Timing of Cardio-Kidney Protection With SGLT2 Inhibitors: Insights From Four Large-Scale Placebo-Controlled Outcome Trials. Circulation. 2024 May 11. doi: 10.1161/CIRCULATIONAHA.124.069382. Epub ahead of print. PMID: 38733145.

DAPA-HF, DELIVER, CANVAS Program, CREDENCE (late-breaking clinical trial at ESC-HFA)

1. Neuen BL, Claggett BL, Perkovic V, Jardine M, Heerspink HJL, Mahaffey KW, McMurray JJV, Solomon SD, Vaduganathan M. Timing of Cardio-Kidney Protection With SGLT2 Inhibitors: Insights From Four Large-Scale Placebo-Controlled Outcome Trials. Circulation. 2024 May 11. doi: 10.1161/CIRCULATIONAHA.124.069382. Epub ahead of print. PMID: 38733145.

FINEARTS-HF (one late-breaking clinical trial presentation at ESC-HFA)

1. Vaduganathan M, Claggett BL, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Desai AS, Jhund PS, Viswanathan P, Bomfim Wirtz A, Schloemer P, Lay- Flurrie J, McMurray JJV, Solomon SD. Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial. Eur J Heart Fail. 2024 May 14. doi: 10.1002/ejhf.3253. Epub ahead of print. PMID: 38742248.
2. Solomon SD, Ostrominski JW, Vaduganathan M, Claggett B, Jhund PS, Desai AS, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Abidin IZ, Alcocer-Gamba MA, Atherton JJ, Bauersachs J, Ma CS, Chiang CE, Chioncel O, Chopra V, Comin-Colet J, Filippatos G, Fonseca C, Gajos G, Goland S, Goncalvesová E, Kang SM, Katova T, Kosiborod MN, Latkovskis G, Lee AP, Linssen GCM, Llamas-Esperón G, Mareev V, Martinez FA, Melenovský V, Merkely B, Nodari S, Petrie MC, Saldarriaga CI, Saraiva JFK, Sato N, Schou M, Sharma K, Troughton R, Udell JA, Ukkonen H, Vardeny O, Verma S, von Lewinski D, Voronkov LG, Yilmaz MB, Zieroth S, Lay-Flurrie J, van Gameren I, Amarante F, Viswanathan P, McMurray Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial. Eur J Heart Fail. 2024 May 11. doi: 10.1002/ejhf.3266. Epub ahead of print. PMID: 38733212.
3. Ostrominski JW, Aggarwal R, Claggett BL, Kulac IJ, Desai AS, Jhund PS, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Lay-Flurrie J, Viswanathan P, McMurray JJV, Solomon SD, Vaduganathan M. Generalizability of the Spectrum of Kidney Risk in the FINEARTS-HF Trial to US Adults with Heart Failure. J Card Fail. 2024 May 11:S1071-9164(24)00156-8. doi: 10.1016/j.cardfail.2024.04.015. Epub ahead of print. PMID: 38740173.
4. Ostrominski JW, Claggett BL, Miao ZM, Mc Causland FR, Anand IS, Desai AS, Jhund PS, Lam CSP, Pfeffer MA, Pitt B, Zannad F, Zile MR, Bomfim Wirtz A, Lay-Flurrie J, Viswanathan P, McMurray JJV, Solomon SD, Vaduganathan M. Cardiovascular-Kidney-Metabolic Overlap in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Trial-Level Analysis. J Am Coll Cardiol. 2024 May 9:S0735-1097(24)07204-8. doi: 10.1016/j.jacc.2024.05.005. Epub ahead of print. PMID: 38744407.

REVIVED-BCIS2 (late-breaking clinical trial at EuroPCR)

1. Ezad SM, McEntegart M, Dodd M, Didagelos M, Sidik N, Li Kam Wa M, Morgan HP, Pavlidis A, Weerackody R, Walsh SJ, Spratt JC, Strange J, Ludman P, Chiribiri A, Clayton T, Petrie MC, O’Kane P, Perera D. Impact of Anatomical and Viability-guided Completeness of Revascularization on Clinical Outcomes in Ischemic Cardiomyopathy. J Am Coll Cardiol. Online 2024 May 15. https://doi.org/10.1016/j.jacc.2024.04.043

EMPRESS-MI

1. Carberry J, Petrie MC, Lee MMY, Brooksbank K, Campbell RT, Good R, Jhund PS, Kellman P, Lang NN, Mangion K, Mark PB, McConnachie A, McMurray JJV, Meyer B, Orchard V, Shaukat A, Watkins S, Welsh P, Sattar N, Berry C, Docherty Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS-MI): rationale and design. ESC Heart Fail. 2024 May 7. doi: 10.1002/ehf2.14830. Epub ahead of print. PMID: 38715187.

DELIVER, DAPA-HF

1. Kondo T, Mogensen UM, Talebi A, Gasparyan SB, Campbell RT, Docherty KF, de Boer RA, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Sabatine MS, Bengtsson O, Sjöstrand M, Vaduganathan M, Solomon SD, Jhund PS, McMurray Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial. J Am Coll Cardiol. 2024 May 21;83(20):1973-1986. doi: 10.1016/j.jacc.2024.03.385. Epub 2024 Mar 25. PMID: 38537918.
2. Lassen MCH, Ostrominski JW, Inzucchi SE, Claggett BL, Kulac I, Jhund P, de Boer RA, Hernandez AF, Kosiborod MN, Lam CSP, Martinez FA, Shah SJ, Desai AS, Petersson M, Langkilde AM, Docherty KF, McMurray JJV, Solomon SD, Vaduganathan M. Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose-lowering therapy: A pre-specified analysis of the DELIVER trial. Eur J Heart Fail. 2024 May 15. doi: 10.1002/ejhf.3269. Epub ahead of print. PMID: 38745498.
3. Pabón MA, Wang X, Lam CSP, O’Meara E, Vaduganathan M, Claggett BL, Foà A, Lu H, Langkilde AM, De Boer RA, Desai AS, Hernandez AF, Inzucchi SE, Jhund PS, Kosiborod MN, Martinez FA, Shah SJ, Petersson M, McMurray JJV, Solomon SD, Vardeny O. Sex Differences in Heart Failure With Improved Ejection Fraction: The DELIVER Trial. J Am Coll Cardiol HF. Online 2024 May 8. https://doi.org/10.1016/j.jchf.2024.03.011
4. Kondo T, Jhund PS, Gasparyan SB, Yang M, Claggett BL, McCausland FR, Tolomeo P, Vadagunathan M, Heerspink HJL, Solomon SD, McMurray A hierarchical kidney outcome using win statistics in patients with heart failure from the DAPA-HF and DELIVER trials. Nat Med. 2024 May 6. doi: 10.1038/s41591-024-02941-8. Epub ahead of print. PMID: 38710952.
5. Yang M, Kondo T, Talebi A, Jhund PS, Docherty KF, Claggett BL, Vaduganathan M, Bachus E, Hernandez AF, Lam CSP, Inzucchi SE, Martinez FA, de Boer RA, Kosiborod MN, Desai AS, Køber L, Ponikowski P, Sabatine MS, Solomon SD, McMurray Dapagliflozin and quality of life measured using the EuroQol 5-dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction. Eur J Heart Fail. 2024 May 3. doi: 10.1002/ejhf.3263. Epub ahead of print. PMID: 38700986.

DELIVER, PARAGON-HF, I-PRESERVE

1. McDowell K, Kondo T, Talebi A, Teh K, Bachus E, de Boer RA, Campbell RT, Claggett B, Desai AS, Docherty KF, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Simpson J, Vaduganathan M, Jhund PS, Solomon SD, McMurray Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2024 May 1;9(5):457-465. doi: 10.1001/jamacardio.2024.0284. PMID: 38536153; PMCID: PMC10974691.
2. Foà A, Vaduganathan M, Claggett BL, Pabon MA, Lu H, Pfeffer MA, Packer M, Vardeny O, Rouleau JL, Lefkowitz M, Mentz RJ, Jhund PS, Desai AS, McMurray JJV, Solomon SD. Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection Fraction. J Am Coll Cardiol. 2024 May 7;83(18):1731-1739. doi: 10.1016/j.jacc.2024.02.035. Epub 2024 Mar 25. PMID: 38537919.

PARAGON-HF

1. Foà A, Vaduganathan M, Claggett BL, Pabon MA, Lu H, Pfeffer MA, Packer M, Vardeny O, Rouleau JL, Lefkowitz M, Mentz RJ, Jhund PS, Desai AS, McMurray JJV, Solomon SD. Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection Fraction. J Am Coll Cardiol. 2024 May 7;83(18):1731-1739. doi: 10.1016/j.jacc.2024.02.035. Epub 2024 Mar 25. PMID: 38537919.

RALES and EMPHASIS-HF

1. Matsumoto S, Henderson AD, Shen L, Yang M, Swedberg K, Vaduganathan M, van Veldhuisen DJ, Solomon SD, Pitt B, Zannad F, Jhund PS, McMurray Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Impaired Renal Function. J Am Coll Cardiol. 2024 May 6:S0735-1097(24)06945-6. doi: 10.1016/j.jacc.2024.03.426. Epub ahead of print. PMID: 38739064.
2. Yu YL, Siwy J, An DW, González A, Hansen T, Latosinska A, Pellicori P, Ravassa S, Mariottoni B, Verdonschot JA, Ahmed F, Petutschnigg J, Rossignol P, Heymans S, Cuthbert JJ, Girerd N, Clark AL, Verhamme P, Nawrot TS, Janssens S, Cleland JG, Zannad F, Diez J, Mischak H, Ferreira JP, Staessen JA; HOMAGE investigators. Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial. Heart. 2024 May 9:heartjnl-2023-323796. doi: 10.1136/heartjnl-2023-323796. Epub ahead of print. PMID: 38729636.

HOMAGE

1. Yu YL, Siwy J, An DW, González A, Hansen T, Latosinska A, Pellicori P, Ravassa S, Mariottoni B, Verdonschot JA, Ahmed F, Petutschnigg J, Rossignol P, Heymans S, Cuthbert JJ, Girerd N, Clark AL, Verhamme P, Nawrot TS, Janssens S, Cleland JG, Zannad F, Diez J, Mischak H, Ferreira JP, Staessen JA; HOMAGE investigators. Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial. Heart. 2024 May 9:heartjnl-2023-323796. doi: 10.1136/heartjnl-2023-323796. Epub ahead of print. PMID: 38729636.

Iron

1. Packer M, Anker SD, Butler J, Cleland JGF, Kalra PR, Mentz RJ, Ponikowski P, Talha KM. Redefining Iron Deficiency in Patients With Chronic Heart Failure. Circulation. 2024 May 11. doi: 10.1161/CIRCULATIONAHA.124.068883. Epub ahead of print. PMID: 38733252.
2. Packer M, Anker SD, Butler J, Cleland JGF, Kalra PR, Mentz RJ, Ponikowski P. Identification of three mechanistic pathways for iron-deficient heart failure. Eur Heart J. 2024 May 11:ehae284. doi: 10.1093/eurheartj/ehae284. Epub ahead of print. PMID: 38733250.
3. Packer M, Anker SD, Butler J, Cleland JGF, Kalra PR, Mentz RJ, Ponikowski P, Talha KM. Critical re-evaluation of the identification of iron deficiency states and effective iron repletion strategies in patients with chronic heart failure. Eur J Heart Fail. 2024 May 10. doi: 10.1002/ejhf.3237. Epub ahead of print. PMID: 38727791.

Danish nationwide cohorts

1. Zahir Anjum D, Strange JE, Fosbøl E, Garred CH, Elmegaard M, Andersson C, Jhund PS, McMurray JJV, Petrie MC, Kober L, Schou M. Use of medical therapy and risk of clinical events according to frailty in heart failure patients - A real-life cohort study. Eur J Heart Fail. 2024 May 3. doi: 10.1002/ejhf.3249. Epub ahead of print. PMID: 38700461.
2. Garred CH, Malmborg M, Malik ME, Zahir D, Christensen DM, Arulmurugananthavadivel A, Fosbøl EL, Gislason G, McMurray JJV, Petrie MC, Andersson C, Køber L, Schou M. Age-specific mortality trends in heart failure over 25 years: a retrospective Danish nationwide cohort study. Lancet Healthy Longev. 2024 May;5(5):e326-e335. doi: 10.1016/S2666-7568(24)00029-1. PMID: 38705151.

 

---

First published: 23 May 2024